#今日行業(yè)熱點(diǎn)#

①The New England Journal of Medicine：Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid

臨床試驗(yàn)：重組人源化抗甲狀腺素運(yùn)載蛋白淀粉樣變（ATTR）抗體NI006用于去除心臟ATTR以改善心功能障礙的Ⅰ期臨床數(shù)據(jù)

DOI: 10.1056/NEJMoa2303765

②The New England Journal of Medicine：Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts

臨床試驗(yàn)：全人源單克隆抗體度匹魯單抗（Dupilumab）用于嗜酸性粒細(xì)胞計(jì)數(shù)提示的2型炎癥的慢性阻塞性肺疾病(COPD)

DOI: 10.1056/NEJMoa2303951

③The New England Journal of Medicine：Microbial peptides activate tumour-infiltrating lymphocytes in glioblastoma

臨床試驗(yàn)：人源化IgG1單克隆抗體Peresolimab用于成人類風(fēng)濕關(guān)節(jié)炎的Ⅱ期試驗(yàn)

DOI: 10.1056/NEJMoa2209856

④Journal of Thoracic Oncology：Clinical benefit from immunotherapy in patients with small cell lung cancer is associated with tumor capacity for antigen presentation

小細(xì)胞肺癌(SCLC)患者對免疫檢查點(diǎn)阻斷(ICB)應(yīng)答與腫瘤抗原呈遞能力相關(guān)

DOI: 10.1016/j.jtho.2023.05.008

⑤Journal of Translational Medicine：CEBPG suppresses ferroptosis through transcriptional control of SLC7A11 in ovarian cancer

CEBPG通過轉(zhuǎn)錄調(diào)控SLC7A11抑制卵巢癌(OC)細(xì)胞鐵死亡的內(nèi)在機(jī)制

DOI: 10.1186/s12967-023-04136-0

⑥Breast Cancer Research and Treatment：Classification of breast tumors by using a novel approach based on deep learning methods and feature selection

觀點(diǎn)：一種基于深度學(xué)習(xí)和特征選擇的乳腺腫瘤分類方法

DOI: 10.1007/s10549-023-06970-8

⑦全球新靶點(diǎn)的強(qiáng)效及選擇性單克隆抗體(mAb)LAE102針對實(shí)體瘤的I/II期臨床研究（IND）獲FDA批準(zhǔn)

⑧國內(nèi)首個(gè)靶向 Nectin-4 ADC 創(chuàng)新藥9MW2821 的臨床前研究成果發(fā)表，結(jié)構(gòu)更穩(wěn)定，安全性更佳

⑨有望用于降糖、減肥、代謝綜合征等多種代謝性疾病的長效GLP-1類創(chuàng)新結(jié)構(gòu)多肽藥物RAY1225Ⅰ期臨床試驗(yàn)完成首例受試者入組

⑩抗體-細(xì)胞因子融合蛋白SHR-2001獲國家藥品監(jiān)督管理局批準(zhǔn)用于系統(tǒng)性紅斑狼瘡適應(yīng)癥臨床試驗(yàn)

?

科學(xué)探索的世界充滿挑戰(zhàn)，AtaGenix致敬每一位拓荒者，更致力于成為您信賴的合作伙伴！